Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470837 | 0.89 | GPR119 (0.67) | GPR119KDM4EPKMHPGD | |
| SCHEMBL4097772 | 0.86 | GPR119 (0.60) | GPR119KDM4EPKMHPGD | |
| SCHEMBL15412881 | 0.84 | GPR119 (0.61) | GPR119KDM4EPKMMAPTTHRB | |
| SCHEMBL26635122 | 0.84 | GPR119 (0.58) | GPR119KDM4EPKMHPGD | |
| SCHEMBL20303147 | 0.83 | GPR119 (0.58) | GPR119KDM4EPKMHPGDPRMT5 | |
| SCHEMBL2149117 | 0.83 | GPR119 (0.58) | GPR119KDM4EPKMHPGDPRMT5 | |
| SCHEMBL7367546 | 0.83 | GPR119 (0.57) | GPR119KDM4EPKMHPGD | |
| Ethylene SCHEMBL8479448 | 0.83 | GPR119 (0.57) | GPR119KDM4EPKMHPGD | |
| SCHEMBL30824931 | 0.81 | GPR119 (0.56) | GPR119KDM4EPKMHPGD | |
| SCHEMBL30824932 | 0.81 | GPR119 (0.56) | GPR119KDM4EPKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-5994356-A | ANTICOAGULANT | KARL THOMAE (DE) | 1999-11-30 | — | — | US | disclosed |
| EP-0892783-A1 | CARBOXYLIC ACID DERIVATIVES WITH AN AGGREGATION-INHIBITING ACTION | Dr. Karl Thomae GmbH (DE) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997037975-A1 | CARBOXYLIC ACID DERIVATIVES WITH AN AGGREGATION-INHIBITING ACTION | DR. KARL THOMAE GMBH (DE) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GCGR, GLP1R | GPR119 1/4885KDM4E 2700/4885PKM 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.